Advertisement

Management of delirium in Parkinson’s disease

  • Georg EbersbachEmail author
  • Chi Wang Ip
  • Stephan Klebe
  • Jiri Koschel
  • Stefan Lorenzl
  • Christoph Schrader
  • Christian Winkler
  • Christiana Franke
Neurology and Preclinical Neurological Studies - Review Article
  • 58 Downloads

Abstract

Delirium is an acute and fluctuating disturbance of attention and awareness. Pre-existing cognitive disturbances or dementia are the most significant risk factors for developing delirium and precipitating factors such as drug treatment, infections, trauma, or surgery may trigger delirium. Patients with Parkinson’s disease (PD) are at an increased risk for delirium which may be underdiagnosed due to phenomenological overlap between delirium and chronic neuropsychiatric features of PD or side effects of dopaminergic medication. Prognosis of delirium is detrimental in many cases including permanent cognitive decline, motor impairment, and increased mortality. Management of delirium comprises of pharmacological and non-pharmacological measures. Pharmacotherapy is aimed at treating medical precipitating factors such as infections, pain, and sleep deprivation. Adjustments of anti-parkinsonian medication are recommended to prevent or treat delirium, but no hard evidence in this respect is available from controlled studies. Administration of neuroleptics and other psychoactive drugs in the treatment of delirium is controversially discussed and should be reserved for patients with severe agitation or distressing psychosis. Non-pharmacological interventions to prevent or palliate delirium are based on withdrawing precipitating or distressing factors, and to provide sensory, emotional and environmental support. Appropriate instruments to detect and assess delirium in PD are needed, and efforts are warranted to improve understanding and treatment of this severe and common disorder.

Keywords

Delirium Parkinson’s disease Quetiapine Psychosis Dementia 

Notes

Compliance with ethical standards

Conflict of interest

Prof. Georg Ebersbach, MD: Consultancy fees: AOK Nordost. Fees for advisory board participation: AbbVie Pharma, Grünenthal Pharma, Neuroderm Inc., Stada Pharma, Neurocrine Inc. Lecture fees: AbbVie Pharma, BIAL Pharma, Britannia Pharma, Desitin Pharma, Licher GmbH, UCB Pharma, Zambon Pharma, Royalties: Kohlhammer Verlag, Thieme Verlag. Dr. Chi Wang Ip, MD Fees for advisory board participation Merz Pharmaceuticals, LLC, Ipsen Pharm and TEVA; Funding for travel: Desitin Pharma, Ipsen Pharm, Merz Pharmaceuticals, LLC, Allergan, Inc.; Lecture fees: Merz, Ipsen Pharm, TEVA, Allergan, Inc. Prof. Stephan Klebe, MD: Lecture fees: Allergan Pharma, Merz Pharmaceuticals ; Royalties: Thieme Verlag. Prof. Christian Winkler, MD PhD: Fees for adivsory board participation: AbbVie Pharma, BIAL Pharma, UCB Pharma. Lecture fees: AbbVie Pharma, BIAL Pharma, Licher MT, UCB Pharma. Prof. Stefan Lorenzl, MD: Lecture fees: AbbVie Pharma, UCB Pharma, Desitin Pharma, Royalties: Kohlhammer Verlag, Thieme Verlag. Dr. Christoph Schrader: Consultancy fees from Abbvie Deutschland, Fees for advisory board participation: AbbVie Pharma, Lecture fees: Abbvie Deutschland, Desitin Pharma, Merz Pharmaceuticals ; Royalties: Elsevier. Christiana Franke, and MD declares no conflict of interest.

References

  1. Boettger S, Jenewein J, Breitbart W (2015) Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects. Palliat Support Care 13:1079–1085CrossRefGoogle Scholar
  2. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S (1997) The Memorial Delirium Assessment Scale. J Pain Symptom Manag 13:128–137CrossRefGoogle Scholar
  3. Chen S, Shi L, Liang F, Xu L, Desislava D, Wu Q, Zhang J (2016) Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials. Mol Neurobiol 53:4046–4053CrossRefGoogle Scholar
  4. Cole MG, McCusker J, Bellavance F, Primeau FJ, Bailey RF, Bonnycastle MJ, Laplante J (2002) Systematic detection and multidisciplinary care of delirium in older medical inpatients: a randomized trial. CMAJ 167:753–759Google Scholar
  5. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ (1990) Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord 5:280–285CrossRefGoogle Scholar
  6. Feast AR, White N, Lord K, Kupeli N, Vickerstaff V, Sampson EL (2018) Pain and delirium in people with dementia in the acute general hospital setting. Age Ageing 47:841–846CrossRefGoogle Scholar
  7. Figueroa-Ramos MI, Arroyo-Novoa CM, Lee KA, Padilla G, Puntillo KA (2009) Sleep and delirium in ICU patients: a review of mechanisms and manifestations. Intensive Care Med 35:781–795CrossRefGoogle Scholar
  8. Flaherty JH, Steele DK, Chibnall JT, Vasudevan VN, Bassil N, Vegi S (2010) An ACE unit with a delirium room may improve function and equalize length of stay among older delirious medical inpatients. J Gerontol A Biol Sci Med Sci 65:1387–1392CrossRefGoogle Scholar
  9. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171CrossRefGoogle Scholar
  10. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844CrossRefGoogle Scholar
  11. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59(Suppl 3):3–7Google Scholar
  12. Inouye SK (2000) Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 32:257–263CrossRefGoogle Scholar
  13. Inouye SK, Baker DI, Fugal P, Bradley EH, Project HD (2006) Dissemination of the hospital elder life program: implementation, adaptation, and successes. J Am Geriatr Soc 54:1492–1499CrossRefGoogle Scholar
  14. Inouye SK, Kosar CM, Tommet D, Schmitt EM, Puelle MR, Saczynski JS, Marcantonio ER, Jones RN (2014a) The CAM-S: development and validation of a new scoring system for delirium severity in 2 cohorts. Ann Intern Med 160:526–533CrossRefGoogle Scholar
  15. Inouye SK, Westendorp RG, Saczynski JS (2014b) Delirium in elderly people. Lancet 383:911–922CrossRefGoogle Scholar
  16. Larsen KA, Kelly SE, Stern TA, Bode RH Jr, Price LL, Hunter DJ, Gulczynski D, Bierbaum BE, Sweeney GA, Hoikala KA, Cotter JJ, Potter AW (2010) Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial. Psychosomatics 51:409–418CrossRefGoogle Scholar
  17. Lawson RA, McDonald C, Burn DJ (2018) Defining delirium in idiopathic Parkinson’s disease: a systematic review. Parkinsonism Relat Disord.  https://doi.org/10.1016/j.parkreldis.2018.09.025 Google Scholar
  18. Levkoff SE, Evans DA, Liptzin B, Cleary PD, Lipsitz LA, Wetle TT, Reilly CH, Pilgrim DM, Schor J, Rowe J (1992) Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med 152:334–340CrossRefGoogle Scholar
  19. Lonergan E, Britton AM, Luxenberg J, Wyller T (2007) Antipsychotics for delirium. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD005594.pub2 Google Scholar
  20. Lubomski M, Rushworth RL, Tisch S (2015) Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry 86:324–330CrossRefGoogle Scholar
  21. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 89:88–100CrossRefGoogle Scholar
  22. Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM (2016) Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc 64:705–714CrossRefGoogle Scholar
  23. Park M, Tang JH (2007) Changing the practice of physical restraint use in acute care. J Gerontol Nurs 33:9–16Google Scholar
  24. Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 340:757–763CrossRefGoogle Scholar
  25. Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS (2006) Multicomponent geriatric intervention for elderly inpatients with delirium: a randomized, controlled trial. J Gerontol A Biol Sci Med Sci 61:176–181CrossRefGoogle Scholar
  26. Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, Durif F, Bourdeix I (2004) Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75:689–695CrossRefGoogle Scholar
  27. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168:508–513CrossRefGoogle Scholar
  28. Saczynski JS, Marcantonio ER, Quach L, Fong TG, Gross A, Inouye SK, Jones RN (2012) Cognitive trajectories after postoperative delirium. N Engl J Med 367:30–39CrossRefGoogle Scholar
  29. Sands MB, Dantoc BP, Hartshorn A, Ryan CJ, Lujic S (2010) Single question in delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale. Palliat Med 24:561–565CrossRefGoogle Scholar
  30. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, Spears L et al (2009) Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 373:1874–1882CrossRefGoogle Scholar
  31. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):42–80CrossRefGoogle Scholar
  32. Serrano-Duenas M, Bleda MJ (2005) Delirium in Parkinson’s disease patients. A five-year follow-up study. Parkinsonism Relat Disord 11:387–392CrossRefGoogle Scholar
  33. Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N (2001) Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 13:229–242CrossRefGoogle Scholar
  34. Umemura A, Oeda T, Tomita S, Hayashi R, Kohsaka M, Park K, Sugiyama H, Sawada H (2014) Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study. PLoS One 9:e94944CrossRefGoogle Scholar
  35. van Eijk MM, Roes KC, Honing ML, Kuiper MA, Karakus A, van der Jagt M, Spronk PE, van Gool WA, van der Mast RC, Kesecioglu J, Slooter AJ (2010) Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 376:1829–1837CrossRefGoogle Scholar
  36. Vardy ER, Teodorczuk A, Yarnall AJ (2015) Review of delirium in patients with Parkinson’s disease. J Neurol 262:2401–2410CrossRefGoogle Scholar
  37. Vida S, Galbaud du Fort G, Kakuma R, Arsenault L, Platt RW, Wolfson CM (2006) An 18-month prospective cohort study of functional outcome of delirium in elderly patients: activities of daily living. Int Psychogeriatr 18:681–700CrossRefGoogle Scholar
  38. Wilby KJ, Johnson EG, Johnson HE, Ensom MHH (2017) Evidence-based review of pharmacotherapy used for Parkinson’s disease psychosis. Ann Pharmacother 51:682–695CrossRefGoogle Scholar
  39. Wilson RS, Hebert LE, Scherr PA, Dong X, Leurgens SE, Evans DA (2012) Cognitive decline after hospitalization in a community population of older persons. Neurology 78:950–956CrossRefGoogle Scholar
  40. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA (2010) Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 304:443–451CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Movement Disorders ClinicKliniken Beelitz GmbHBeelitz-HeilstättenGermany
  2. 2.Department of NeurologyUniversity Hospital WürzburgWürzburgGermany
  3. 3.Department of NeurologyUniversity Hospital EssenEssenGermany
  4. 4.Parkinson-Klinik OrtenauWolfachGermany
  5. 5.Professorship for Interdisciplinary Research in Palliative Care, Institute of Nursing Science and PracticeParacelsus Medical UniversitySalzburgAustria
  6. 6.Department of Palliative CareKlinikum der Universität München, Ludwig-Maximilians-UniversityMunichGermany
  7. 7.University Hospital AgathariedHaushamGermany
  8. 8.Department of Neurology and Clinical NeurophysiologyHannover Medical SchoolHannoverGermany
  9. 9.Department of NeurologyLindenbrunn HospitalCoppenbrüggeGermany
  10. 10.Department of NeurologyCharité-Universitätsmedizin BerlinBerlinGermany

Personalised recommendations